Dario Padovani

Capricorn Partners NV (Capricorn) is an independent European licensed manager of private and public equity investment funds which was founded in 1993 as a joint venture between Dr Jos B. Peeters and Baring Venture Partners Ltd. In 1999, Capricorn became a fully partner-owned, independent firm. It is headquartered in Leuven, Belgium.

KBC Securities NV is a broker/dealer firm headquartered in Brussels, Belgium. The firm was founded in 1998 and is a wholly owned subsidiary of KBC Bank NV, itself a subsidiary of KBC Groupe SA (EBR: KBC). KBC Securities provides liquidity and order execution services to institutional clients internationally, from investment banks to mutual funds and private investors.

Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium.

Abbott Group Ltd. manufactures doors and timber products. It specializes in the supply of fenestration products to homebuilders. The company's products include PVC-U windows, doors and cavity closers. Abbott Group is headquartered in Halisham, UK

CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium.

Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain.

MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium.

Biotechnological Enzymatic Catalyse NV develops, produces and commercializes enzymatic systems for food preservation. It engages in the research, development and manufacturing of antimicrobial products for food safety. The firm's solutions are designed for use in the following: dairy products, fruit and vegetable juices, sauces and dressings and liquid egg products. The company was founded in 1992 and is headquartered in Ghent, Belgium.

Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France.

INVESTSUD SA (INVESTSUD) is an independent venture capital firm founded in 1983. Investsud SA is headquartered in Marche-en-Famenne, Belgium.

Vesalius Biocapital Partners SARL (Vesalius Biocapital Partners) is an independent venture capital firm founded in 2007 by Stéphane Verdood. The firm is headquartered in Luxembourg.

Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.

ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands.

The Belgian Venture Capital & Private Equity Association provides equity capital to enterprises not quoted on a stock market. The firm develops new products and technologies to expand working capital, to make acquisitions or to strengthen a company’s balance sheet. The company was founded in 1986 and is headquartered in Brussels, Belgium.

PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

QBIC Venture Partners BVBA (QBIC Venture Partners) is a venture capital firm founded in 2012 by Marc Zabeau. The firm is headquartered in Belgium.

Bioxodes SA develops pharmaceutical products. Its programme Ir-CPI, is the first in a novel class of antithrombotics, and is developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. The company was founded by Edmond Godfroid and Michel Guyaux on April 20, 2010 and is headquartered in Marche-en-Famenne, Belgium.

Bio-Sourcing SA develops and markets biological drugs for veterinary use. The firm focuses on farm animal health and companion animal health. The company was founded by Bertrand Mérot in June 2011 and is headquartered in Liege, Belgium.

Unifly NV specializes in aviation software development. Its platform connects ANSP?s and official entities with drone operators. The firm's products include Launchpad, PRO, sentry, and connect. The company was founded by Koen Meuleman, Hans Schrauwen, J?rgen Verstaen, and Andres Van Swalm and is headquartered in Antwerp, Belgium.

Pharmafluidics NV develops micro chip liquid chromatography cartridges for analysis of complex biological samples. The company was founded by Wim De Malsche, Joeri Denayer, Gert Desme and Paul Godelieve Jacobs in 2010 and is headquartered in Ghent, Belgium.

Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium.

EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium.

DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020.

Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.

Agricells SA is a Belgian company that specializes in research and development for agriculture using biosolutions such as biocontrol, biostimulant, and biofertilizer. The company is based in Marche-en-Famenne, Belgium. The company focuses on innovation, greentech, and biotechnologies in the field of agriculture. Agricells was founded in 2020 by Maxence Semacoy Albertini and Vincent Vandamme, with Maxence Semacoy Albertini serving as the CEO since 2020.